Precision BioSciences, Inc. (DTIL) is a Biotechnology company in the Healthcare sector, currently trading at $7.23. It has a SharesGrow Score of 56/100, indicating a above average investment profile with 2 out of 7 criteria passed.
Analyst consensus target is DTIL = $19 (+162.8% upside).
Valuation: DTIL trades at a trailing Price-to-Earnings (P/E) of -1.7 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.27.
Financials: revenue is $34M, +28.3%/yr average growth. Net income is $47M (loss), growing at -196.2%/yr. Net profit margin is -136% (negative). Gross margin is 92% (+27.9 pp trend).
Balance sheet: total debt is $29M against $92M equity (Debt-to-Equity (D/E) ratio 0.31, conservative). Current ratio is 13.32 (strong liquidity). Debt-to-assets is 18.7%. Total assets: $154M.
Analyst outlook: 9 / 12 analysts rate DTIL as buy (75%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 58/100 (Partial), Past 25/100 (Fail), Health 67/100 (Partial), Moat 50/100 (Partial), Future 85/100 (Pass), Income 10/100 (Fail).
